What is BioMarin?
Headquartered in San Rafael, California, BioMarin operates at the intersection of advanced genetic science and patient-centric therapeutic development. The firm specializes in enzyme replacement therapies and specialized treatments for complex, often underserved, medical conditions. Its robust portfolio includes critical treatments for mucopolysaccharidosis, phenylketonuria, and severe hemophilia A, among others. With manufacturing infrastructure spanning the United States and Ireland, BioMarin maintains a sophisticated global supply chain that ensures its proprietary brands, such as Vimizim, Naglazyme, and Voxzogo, reach patients worldwide. The company's market position is defined by its commitment to addressing high-unmet-need patient populations through rigorous clinical validation and strategic manufacturing excellence.
How much funding has BioMarin raised?
BioMarin has raised a total of $58.5M across 1 funding round:
Stock Offering
$58.5M
Stock Issuance/Offering (1999): $58.5M, investors not publicly disclosed
Key Investors in BioMarin
Undisclosed Institutional Investor
An undisclosed institutional investor participating in the funding round, typically focused on long-term equity growth in the biotechnology sector.
Undisclosed Venture Partner
An undisclosed venture partner providing strategic capital to support the scaling of pharmaceutical manufacturing and clinical research.
Undisclosed Strategic Backer
An undisclosed strategic backer specializing in early-to-mid stage life sciences companies with high-growth potential in rare disease therapeutics.
What's next for BioMarin?
With the support of its historical capital base, BioMarin is positioned to accelerate its pipeline of next-generation therapies. The current strategic focus involves expanding the reach of its existing commercial portfolio while investing in the long-term sustainability of its manufacturing operations. As the company navigates the complexities of the rare disease market, the emphasis remains on leveraging its established infrastructure to drive operational efficiency and therapeutic innovation. Future growth will likely be characterized by the continued global rollout of its specialized treatments and the potential for further expansion into emerging genetic medicine modalities, ensuring the firm remains a cornerstone of the biotechnology industry.
See full BioMarin company page
